195 related articles for article (PubMed ID: 23951051)
21. A2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis.
Mills JH; Kim DG; Krenz A; Chen JF; Bynoe MS
J Immunol; 2012 Jun; 188(11):5713-22. PubMed ID: 22529293
[TBL] [Abstract][Full Text] [Related]
22. Mannan-MOG35-55 Reverses Experimental Autoimmune Encephalomyelitis, Inducing a Peripheral Type 2 Myeloid Response, Reducing CNS Inflammation, and Preserving Axons in Spinal Cord Lesions.
Dagkonaki A; Avloniti M; Evangelidou M; Papazian I; Kanistras I; Tseveleki V; Lampros F; Tselios T; Jensen LT; Möbius W; Ruhwedel T; Androutsou ME; Matsoukas J; Anagnostouli M; Lassmann H; Probert L
Front Immunol; 2020; 11():575451. PubMed ID: 33329540
[TBL] [Abstract][Full Text] [Related]
23. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE.
Skundric DS; Dai R; Zakarian VL; Bessert D; Skoff RP; Cruikshank WW; Kurjakovic Z
J Neurosci Res; 2005 Mar; 79(5):680-93. PubMed ID: 15682385
[TBL] [Abstract][Full Text] [Related]
24. Endogenous T Cell Receptor Rearrangement Represses Aggressive Central Nervous System Autoimmunity in a TcR-Transgenic Model on the Non-Obese Diabetic Background.
Yeola AP; Ignatius Arokia Doss PM; Baillargeon J; Akbar I; Mailhot B; Balood M; Talbot S; Anderson AC; Lacroix S; Rangachari M
Front Immunol; 2019; 10():3115. PubMed ID: 32010149
[TBL] [Abstract][Full Text] [Related]
25. Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein.
Lyons JA; Ramsbottom MJ; Cross AH
Eur J Immunol; 2002 Jul; 32(7):1905-13. PubMed ID: 12115610
[TBL] [Abstract][Full Text] [Related]
26. Chronological changes of CD4(+) and CD8(+) T cell subsets in the experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis.
Sonobe Y; Jin S; Wang J; Kawanokuchi J; Takeuchi H; Mizuno T; Suzumura A
Tohoku J Exp Med; 2007 Dec; 213(4):329-39. PubMed ID: 18075237
[TBL] [Abstract][Full Text] [Related]
27. CD6 as a potential target for treating multiple sclerosis.
Li Y; Singer NG; Whitbred J; Bowen MA; Fox DA; Lin F
Proc Natl Acad Sci U S A; 2017 Mar; 114(10):2687-2692. PubMed ID: 28209777
[TBL] [Abstract][Full Text] [Related]
28. Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis.
Gan Y; Liu R; Wu W; Bomprezzi R; Shi FD
J Neuroimmunol; 2012 Jun; 247(1-2):9-15. PubMed ID: 22503411
[TBL] [Abstract][Full Text] [Related]
29. Development of a CD19 PET tracer for detecting B cells in a mouse model of multiple sclerosis.
Stevens MY; Cropper HC; Lucot KL; Chaney AM; Lechtenberg KJ; Jackson IM; Buckwalter MS; James ML
J Neuroinflammation; 2020 Sep; 17(1):275. PubMed ID: 32948198
[TBL] [Abstract][Full Text] [Related]
30. Increased severity of experimental allergic encephalomyelitis in lyn-/- mice in the absence of elevated proinflammatory cytokine response in the central nervous system.
Du C; Sriram S
J Immunol; 2002 Mar; 168(6):3105-12. PubMed ID: 11884485
[TBL] [Abstract][Full Text] [Related]
31. Monocyte behaviour and tissue transglutaminase expression during experimental autoimmune encephalomyelitis in transgenic CX3CR1
Chrobok NL; Jaouen A; Fenrich KK; Bol JG; Wilhelmus MM; Drukarch B; Debarbieux F; van Dam AM
Amino Acids; 2017 Mar; 49(3):643-658. PubMed ID: 27826792
[TBL] [Abstract][Full Text] [Related]
32. Deletion of IL-33R (ST2) abrogates resistance to EAE in BALB/C mice by enhancing polarization of APC to inflammatory phenotype.
Milovanovic M; Volarevic V; Ljujic B; Radosavljevic G; Jovanovic I; Arsenijevic N; Lukic ML
PLoS One; 2012; 7(9):e45225. PubMed ID: 23028861
[TBL] [Abstract][Full Text] [Related]
33. IC100: a novel anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis.
Desu HL; Plastini M; Illiano P; Bramlett HM; Dietrich WD; de Rivero Vaccari JP; Brambilla R; Keane RW
J Neuroinflammation; 2020 May; 17(1):143. PubMed ID: 32366256
[TBL] [Abstract][Full Text] [Related]
34. Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity.
Mitsdoerffer M; Di Liberto G; Dötsch S; Sie C; Wagner I; Pfaller M; Kreutzfeldt M; Fräßle S; Aly L; Knier B; Busch DH; Merkler D; Korn T
Brain; 2021 Jul; 144(6):1697-1710. PubMed ID: 33693558
[TBL] [Abstract][Full Text] [Related]
35. Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking.
Göbel K; Pankratz S; Schneider-Hohendorf T; Bittner S; Schuhmann MK; Langer HF; Stoll G; Wiendl H; Kleinschnitz C; Meuth SG
J Autoimmun; 2011 Mar; 36(2):106-14. PubMed ID: 21216565
[TBL] [Abstract][Full Text] [Related]
36. The complement system contributes to the pathology of experimental autoimmune encephalomyelitis by triggering demyelination and modifying the antigen-specific T and B cell response.
Hundgeburth LC; Wunsch M; Rovituso D; Recks MS; Addicks K; Lehmann PV; Kuerten S
Clin Immunol; 2013 Mar; 146(3):155-64. PubMed ID: 23352967
[TBL] [Abstract][Full Text] [Related]
37. CD49d/CD29-integrin controls the accumulation of plasmacytoid dendritic cells into the CNS during neuroinflammation.
Garnier A; Laffont S; Garnier L; Kaba E; Deutsch U; Engelhardt B; Guéry JC
Eur J Immunol; 2019 Nov; 49(11):2030-2043. PubMed ID: 31318439
[TBL] [Abstract][Full Text] [Related]
38. Adhesion Molecule Profile and the Effect of Anti-VLA-4 mAb Treatment in Experimental Autoimmune Encephalomyelitis, a Mouse Model of Multiple Sclerosis.
Pyka-Fościak G; Lis GJ; Litwin JA
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563027
[TBL] [Abstract][Full Text] [Related]
39. UCP2 up-regulation within the course of autoimmune encephalomyelitis correlates with T-lymphocyte activation.
Smorodchenko A; Schneider S; Rupprecht A; Hilse K; Sasgary S; Zeitz U; Erben RG; Pohl EE
Biochim Biophys Acta Mol Basis Dis; 2017 Apr; 1863(4):1002-1012. PubMed ID: 28130201
[TBL] [Abstract][Full Text] [Related]
40. Brain-derived neurotrophic factor precursor in the immune system is a novel target for treating multiple sclerosis.
Hu ZL; Luo C; Hurtado PR; Li H; Wang S; Hu B; Xu JM; Liu Y; Feng SQ; Hurtado-Perez E; Chen K; Zhou XF; Li CQ; Dai RP
Theranostics; 2021; 11(2):715-730. PubMed ID: 33391501
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
